Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Sep 1;156(9):987-991.
doi: 10.1001/jamadermatol.2020.1867.

Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer

Affiliations
Observational Study

Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer

Rocío Núñez-Torres et al. JAMA Dermatol. .

Abstract

Importance: Persistent chemotherapy-induced alopecia (pCIA) has been recently described in patients with breast cancer and in its most severe form occurs in up to 10% of these patients. Genetic risk factors associated with pCIA have not been adequately explored.

Objective: To identify genetic variants associated with pCIA.

Design, setting, and participants: In this genetic association study, 215 women with breast cancer treated with docetaxel-based chemotherapy with a follow-up of 1.5 to 10 years after the end of the treatment were recruited retrospectively through 3 hospital oncology units across Spain between 2005 and 2018. Severe pCIA was defined as lack of scalp hair recovery (Common Terminology Criteria for Adverse Events, version 3.0, grade 2) 18 months or more after the end of treatment. Patients with grade 2 pCIA were selected as cases, and those with no sign of residual alopecia 12 months after the end of docetaxel treatment were selected as controls. A genome-wide association study in a discovery phase was conducted, and logistic regression was used to identify variants associated with the risk to develop this adverse effect. The validity of the association was addressed through a replication phase.

Exposures: Docetaxel-based chemotherapy.

Main outcomes and measures: Genotypes of single-nucleotide variants associated with pCIA.

Results: In total, 215 women with breast cancer (median age, 51.6 years; interquartile range, 44-60 years) were recruited (173 patients for the discovery phase and 42 patients for the replication phase). In the discovery phase, ABCB1 genetic variants were associated with risk to develop pCIA. In particular, single-nucleotide variation rs1202179, a regulatory variant located in an enhancer element that interacts with the ABCB1 promoter, was associated with the occurrence of pCIA. This finding was validated in the replication cohort (combined odds ratio, 4.05; 95% CI, 2.46-6.67; P = 3.946 × 10-8). This variant is associated with ABCB1 mRNA expression, and the risk allele was associated with decreased ABCB1 expression levels (P = 1.64 × 10-20).

Conclusions and relevance: This is the first study, to our knowledge, that identifies an association between a regulatory variant in the ABCB1 gene and the occurrence of pCIA in patients with breast cancer who were treated with docetaxel-based therapies. This finding suggests an important insight into the biological mechanisms underlying pCIA and opens the opportunity to explore personalized treatment of these patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Martín reported receiving grants and personal fees from Novartis, Puma, and Roche and receiving personal fees from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, Pharmamar, and Taiho Oncology outside the submitted work. Dr García-Sáenz reported receiving grants from Celgene, Daiichi Sankyo, Eli Lilly and Company, Novartis, and Pfizer outside the submitted work. Dr Bermejo reported receiving personal fees from Merck Sharp & Dohme, Novartis, and Roche outside the submitted work. Dr Lluch reported receiving grants and personal fees from Eisai Co, Novartis, Pfizer, and Roche/Genentech and receiving grants from Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Merck & Co, Pharmamar, and Pierre Fabre outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Manhattan Plot of the Genome-Wide Association Analysis in the Discovery Cohort, Showing the Association Between the Genotypes of 693 898 Single-Nucleotide Variants (SNVs) and Risk of Persistent Chemotherapy-Induced Alopecia
The P values derived by logistic regression analyses on a −log10 scale are plotted against their physical chromosomal position. A P value of 5 × 10−6 was established to determine the threshold of genome-wide significance and suggestive associations (red line).

Comment in

References

    1. Trusson D, Pilnick A. The role of hair loss in cancer identity: perceptions of chemotherapy-induced alopecia among women treated for early-stage breast cancer or ductal carcinoma in situ. Cancer Nurs. 2017;40(2):E9-E16. doi:10.1097/NCC.0000000000000373 - DOI - PubMed
    1. Freites-Martinez A, Chan D, Sibaud V, et al. . Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724-728. doi:10.1001/jamadermatol.2018.5071 - DOI - PMC - PubMed
    1. Martín M, de la Torre-Montero JC, López-Tarruella S, et al. . Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. Breast Cancer Res Treat. 2018;171(3):627-634. doi:10.1007/s10549-018-4855-2 - DOI - PMC - PubMed
    1. Kang D, Kim I-R, Choi E-K, et al. . Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. Oncologist. 2019;24(3):414-420. doi:10.1634/theoncologist.2018-0184 - DOI - PMC - PubMed
    1. Kim GM, Kim S, Park HS, et al. . Chemotherapy-induced irreversible alopecia in early breast cancer patients. Breast Cancer Res Treat. 2017;163(3):527-533. doi:10.1007/s10549-017-4204-x - DOI - PubMed

Publication types

MeSH terms

Substances